HALO News and Press, Halozyme Therapeutics Inc. From 05/21/24

2024-05-21 13:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-21 07:29:59 ET More on Bristol-Myers Squibb Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript) Bristol-Myer...

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE® PR Newswire Updated Prescription Drug User Fee Act goal date of December 29, 2024 SA...

2024-05-15 14:20:39 ET Summary This monthly article series shows aggregate industry metrics in the healthcare sector. All healthcare subsectors are overvalued based on my metrics. Pharmaceuticals/biotechnology has the lowest scores in both value and quality. Invesco S&P 50...

2024-05-09 06:15:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We live in the best of times where life is not capped at 45 or 50 years of age, all thanks to wonderful discoveries in the field of biotechnology. The resources being invested to produce new dr...

2024-05-07 19:32:07 ET Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Conference Call May 7, 2024 4:30 p.m. ET Company Participants Tram Bui - Vice President of Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer ...

2024-05-07 16:03:31 ET More on Halozyme Therapeutics Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics Halozyme Therapeutics, Inc. (HALO) Q4 2023 Earnings Call Transcript Halozyme Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS PR Newswire Revenue Increased 21% YOY to $196 million ; Net Income of $77 million ; Adjusted EBITDA of $116 million ; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 ...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

2024-05-06 12:11:46 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb: A Lost Decade? Bristol Myers Squibb: Tough Times Continue Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript Pharma R&D productivity seen improving for the ...